Nektar Therapeutics (NASDAQ: NKTR) kicked off on Friday, up 1.00% from the previous trading day, before settling in for the closing price of $1.00. Over the past 52 weeks, NKTR has traded in a range of $0.46-$1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.42%. While this was happening, its average annual earnings per share was recorded 51.45%. With a float of $178.22 million, this company’s outstanding shares have now reached $184.46 million.
Let’s determine the extent of company efficiency that accounts for 137 employees. In terms of profitability, gross margin is 67.8%, operating margin of -145.96%, and the pretax margin is -180.71%.
Nektar Therapeutics (NKTR) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.38%, while institutional ownership is 74.38%. The most recent insider transaction that took place on Nov 19 ’24, was worth 7,863. In this transaction Chief R&D Officer of this company sold 7,785 shares at a rate of $1.01, taking the stock ownership to the 243,019 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Chief Legal Officer sold 6,407 for $1.01, making the entire transaction worth $6,471. This insider now owns 218,856 shares in total.
Nektar Therapeutics (NKTR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 51.45% per share during the next fiscal year.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Looking closely at Nektar Therapeutics (NASDAQ: NKTR), its last 5-days average volume was 1.8 million, which is a drop from its year-to-date volume of 1.8 million. As of the previous 9 days, the stock’s Stochastic %D was 17.83%. Additionally, its Average True Range was 0.07.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 7.55%, which indicates a significant decrease from 16.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.57% in the past 14 days, which was lower than the 66.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2184, while its 200-day Moving Average is $1.2617. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $1.0300. Second resistance stands at $1.0500. The third major resistance level sits at $1.0700. If the price goes on to break the first support level at $0.9900, it is likely to go to the next support level at $0.9700. Now, if the price goes above the second support level, the third support stands at $0.9500.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
The company with the Market Capitalisation of 188.16 million has total of 184,458K Shares Outstanding. Its annual sales at the moment are 90,120 K in contrast with the sum of -276,060 K annual income. Company’s last quarter sales were recorded 24,120 K and last quarter income was -37,060 K.
